Smith & Nephew (NYSE:SNN;LSE:SN), the global medical technology business, will launch its DYONICS◊ PLAN Hip Impingement Planning System at this week’s American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orleans. Unlike standard imaging tools, DYONICS PLAN is a revolutionary 3D software system that allows surgeons to visualize, assess and generate a comprehensive surgical report for each patient’s unique Femoroacetabular impingement (FAI) surgery before that patient ever enters the operating room.
“Performing impingement surgery in the hip without the report is like putting in a total knee without cutting guides,” says Dr. Bryan Kelly of New York, NY. “DYONICS PLAN takes the guesswork out of every case.”
DYONICS PLAN provides a standardized and repeatable way of assessing hip impingement treatment options based on data from low-dosei CT scans. The software, which is easily installed on a surgeon’s computer, also allows for interactive adjustments based on a surgeon’s clinical experience.
Using the DYONICS PLAN 3D model of the patient’s joint, a surgeon can perform variety of dynamic range-of-motion (ROM) simulations to identify the degree and location of hip impingement. The ROM feature can also be used to individualize a surgical plan based on a patient’s lifestyle or sports-specific motion, or to assess impact of different surgical strategies on patient outcomes. Once finalized, the system generates a comprehensive surgical plan than can be exported into either HTML or PDF format.
“DYONICS PLAN offers surgeons the ability to understand and address a patient’s hip impingement on a level that goes beyond anything possible with standard imaging tools,” explains Brad Cannon, President, Endoscopy, Trauma and Extremities for Smith & Nephew. “Because it tells a more complete story about each patient’s impingement and how best to surgically treat it, it also provides an exceptionally visual tool for patient communication.”
DYONICS PLAN was designed in conjunction with four of the leading surgeons in hip arthroscopy: Dr. Asheesh Bedi of Ann Arbor, MI; Dr. J.W. Thomas Byrd of Nashville, TN; Dr. Bryan Kelly and Dr. Christopher Larson of Edina, MN.
Surgeons can see a demonstration of DYONICS PLAN at the Smith & Nephew booth at this year’s AAOS meeting (#5229 in Hall G) or by visiting DYONICSPLAN.com.
Editor’s Note:
FAI is a condition where the bones of the hip are abnormally shaped. Because they do not fit together perfectly, the hip bones rub against each other and cause damage to the joint, including cartilage damage and bone spurs.
Contacts:
Media
Joe Metzger
Smith & Nephew
Investor/Analyst
Phil Cowdy
Smith & Nephew
+44 (0)20 7401 7646
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management,Sports Medicine and Trauma & Extremities, Smith & Nephew has around 11,000 employees and a presence in more than 90 countries. Annual sales in 2013 were more than $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
i Low-dose scan protocol reduces radiation by approximately 50-percent compared to standard CT protocol. CT Protocol Report, HIPS. Document number 15001984, 2013. Data on file at Smith & Nephew